S-2336 : Still Just a Bill

S. 2336, the "Halting the Epidemic of Addiction and Loss Act of 2025," aims to broaden the scope of opioid overdose reversal agents referenced in grant programs administered by the Department of Health and Human Services (HHS).

• Key Provision: The bill mandates that HHS regulations and guidance for grant programs addressing opioid misuse and use disorders must include all FDA-approved opioid overdose reversal drugs, not just naloxone.
• Update Existing References: Within one year of enactment, HHS must update existing references to opioid overdose reversal drugs in specific grant programs to include all FDA-approved or authorized options.
• Affected Grant Programs: This update applies to:
  • State and Tribal Opioid Response Grants (under section 1003 of the 21st Century Cures Act).
  • Grant program for priority substance use disorder prevention needs of regional and national significance (under section 516 of the Public Health Service Act).

In short, this bill ensures that HHS grant programs are inclusive of all available opioid overdose reversal medications, promoting a comprehensive approach to combating the opioid crisis.